About: Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
Creator	Dalamaga, Maria Karampela, Irene
Source	Elsevier; Medline; PMC
abstract	Since the beginning of the COVID-19 pandemic, researchers have focused on repurposing of existing antibiotics, antivirals and anti-inflammatory drugs to find an effective therapy. Fluoroquinolones are broad spectrum synthetic antimicrobial agents, being chemical derivatives of quinoline, the prodrome of chloroquine. Interestingly, fluoroquinolones may exert antiviral actions against vaccinia virus, papovavirus, CMV, VZV, HSV-1, HSV-2, HCV and HIV. A recent in silico study has shown that the fluoroquinolones, ciprofloxacin and moxifloxacin, may inhibit SARS-CoV-2 replication by exhibiting stronger capacity for binding to its main protease than chloroquine and nelfinavir, a protease inhibitor antiretroviral drug. Remarkably, fluoroquinolones have shown multiple immunomodulatory actions leading to an attenuation of the inflammatory response through the inhibition of pro-inflammatory cytokines. Noteworthy, respiratory fluoroquinolones, levofloxacin and moxifloxacin, constitute fist line therapeutic agents for the management of severe community-acquired pneumonia. They are characterized by advantageous pharmacokinetic properties; higher concentrations in the lungs; and an excellent safety profile comparable to other antibiotics used to treat respiratory infections, such as macrolides and b-lactams. Based on their potential antiviral activity and immunomodulatory properties, the favorable pharmacokinetics and safety profile, we propose the use of respiratory fluoroquinolones as adjuncts in the treatment of SARS-CoV-2 associated pneumonia.
has issue date	2020-06-06(xsd:dateTime)
bibo:doi	10.1016/j.arcmed.2020.06.004
bibo:pmid	32546446
has license	els-covid
sha1sum (hex)	2aeeed1514ac725a28dafd55bf772a510f1755b5
schema:url	https://doi.org/10.1016/j.arcmed.2020.06.004
resource representing a document's title	Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
has PubMed Central identifier	PMC7275144
has PubMed identifier	32546446
schema:publication	Arch Med Res
resource representing a document's body	covid:2aeeed1514ac725a28dafd55bf772a510f1755b5#body_text
is schema:about of	named entity 'Fluoroquinolones' named entity 'Levofloxacin' named entity 'influenza virus' named entity 'hydroxyl radicals' named entity 'active site' named entity 'SARS-CoV-2' named entity 'pro-inflammatory cytokines' named entity 'lungs' named entity 'moxifloxacin' named entity 'COVID-19' named entity 'antiviral' named entity 'anti-malarial' named entity 'protease inhibitor' named entity 'antiviral' named entity 'chloroquine' named entity 'prodrome' named entity 'influenza virus' named entity 'antiviral activity' named entity 'safety profile' named entity 'Dengue virus' named entity 'immunomodulatory' named entity 'metabolites' named entity 'antibiotics' named entity 'fluoroquinolones' named entity 'immunomodulatory' named entity 'levofloxacin' named entity 'remdesivir' named entity 'COVID' named entity 'protease' named entity 'fluoroquinolones' named entity 'quinoline' named entity 'chloroquine' named entity 'AIDS' named entity 'vaccinia virus' named entity 'lung' named entity 'fluoroquinolones' named entity 'herpes simplex virus' named entity 'chloroquine' named entity 'neutrophil' named entity 'pharmacokinetic' named entity 'anti-oxidative' named entity 'oxidative stress' named entity 'viruses' named entity 'azithromycin' named entity 'respiratory infections' named entity 'clinical trials' named entity 'antivirals' named entity 'H1N1' named entity 'varicella-zoster virus' named entity '1, 2' named entity 'COVID-19.' named entity 'levofloxacin' named entity 'chemical derivatives' named entity 'fluoroquinolones' named entity 'SARS-CoV-2' named entity 'macrolides' named entity 'Ebola' named entity 'TNF-α' named entity 'lungs' named entity 'SARS-CoV-2' named entity 'Fluoroquinolones' named entity 'fluoroquinolones' named entity 'fluoroquinolones' named entity 'antiretroviral drug' named entity 'nelfinavir' named entity 'animal model' named entity 'quinoline' named entity 'macrolide' named entity 'antibiotics' named entity 'fluoroquinolones' named entity 'ciprofloxacin' named entity 'hepatitis C virus' named entity 'anti-inflammatory drugs' named entity 'inflammatory response' named entity 'fluoroquinolones' named entity 'serum' named entity 'randomized clinical trials' named entity 'anti-inflammatory' named entity 'HIV' named entity 'papovavirus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software